Drug Discovery@nature.com 20 September 2013

Advertisement iCell® & MyCell® Human Cells Reinvent Discovery Research Ready-made iPSC-derived cells: Cardiomyocytes, neurons, hepatocytes, endothelial cells, and more Made-to-order cells from your donor samples or CDI disease cell lines including cardiomyopathies / arrhythmias, neurological disorders, muscular dystrophies, and more Enabling disease modeling, cell therapy, tissue engineering, and more TABLE OF CONTENTS 20 September 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Neuroscience FOCUS ON NEUROTECHNIQUES The rapid pace of technological innovation has opened up many new avenues for exploring the brain. This special issue focuses on recent advances in methods and techniques that are pushing the frontiers of neuroscience. Read this Focus online: www.nature.com/neuro/focus/neurotechniques     News Top J&J courts biotech in clusters doi:10.1038/nbt0913-769 J&J hopes to accelerate collaborations with academics and early-stage companies by creating innovation centres that assemble J&J scientists, corporate investors and business development executives in a single hub. Full Text Doubts raised over 'read-through' Duchenne drug mechanism doi:10.1038/nbt0913-771 A recent paper resurrects questions about the mechanism of action of PTC Therapeutics' lead drug candidate for Duchenne muscular dystrophy, ataluren (PTC124). Full Text First Axl inhibitor enters clinical trials doi:10.1038/nbt0913-775a The entry of BergenBio's Axl inhibitor BGB324 into Phase I trials is an important milestone for this promising cancer target, which is involved in promoting cell survival and metastasis. Full Text Amgen best-seller challenged by generics doi:10.1038/nbt0913-774b A recent clinical study found a combination of inexpensive drugs was as good as Amgen's biologic Enbrel (etanercept) in treating patients with rheumatoid arthritis. Full Text Analysis Top TLR4 signaling in allergic asthma doi:10.1038/scibx.2013.947 Baylor researchers have opened the door for developing therapeutics that target the causes of allergic asthma. The team still has to show that the new pathway – degradation of fibrinogen into products that activate TLR4 – is relevant to other types of asthma and can be safely targeted. Full Text The epigenetics pipeline doi:10.1038/nrd4091 Epigenetic alterations are found in a number of diseases. This analysis explores the different approaches that are being pursued to exploit the therapeutic potential of epigenetic targets, and provides an overview of the current epigenetics pipeline. Full Text Research Highlights Top HIV: Efficacy through BibNAbs doi:10.1038/nrd4109 Highly potent bispecific broadly neutralizing antibodies (bNAbs) against a broad range of HIV-1 strains show promise for passive immunization against virus. Full Text Cancer: Special delivery service doi:10.1038/nrd4107 Brain-penetrating nanocarriers loaded with dithiazanine iodide, an FDA-approved antihelminthic, could be used for treating glioblastoma multiforme. Full Text G protein-coupled receptors: A double attack on pain doi:10.1038/nrd4105 Ligands targeting a heteromer consisting of the μ-opioid receptor (the target of the analgesic morphine) and a second GPCR could overcome some of the limitations of morphine. Full Text Research & Reviews Top 50 years of hurdles and hope in anxiolytic drug discovery doi:10.1038/nrd4075 This Review analyses the major trends from a database of published preclinical studies on novel anxiolytic agents in the past 50 years, highlighting issues that may have hampered progress and offering recommendations to improve anxiolytic drug discovery. Full Text Disrupting proton dynamics and energy metabolism for novel cancer therapy doi:10.1038/nrc3579 This Review discusses the interplay among metabolism, hypoxia and pH regulation and whether pH-regulatory systems can be targeted for anticancer therapy. Full Text Mitogen-activated protein kinases in innate immunity doi:10.1038/nri3495 This Review summarizes our current understanding of the regulation and function of mitogen-activated protein kinases (MAPKs) in innate immunity, as well as the mechanisms by which pathogens manipulate MAPK activation and the potential of targeting MAPK pathways for the treatment of inflammatory diseases. Full Text Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond doi:10.1038/nrd4099 Sphingosine-1-phosphate (S1P) has a key role in the control of immune cell trafficking and is involved in disorders including cancer and inflammatory diseases. Here, Spiegel and colleagues discuss the ways in which S1P could be therapeutically targeted and highlight recent data from preclinical studies and clinical trials. Full Text Drug Discovery JOBS of the week Research Scholar The University of Queensland Dean, School of Pharmacy University of Connecticut Natural Product Chemist Washington State University Analytical Chemist / Marine Chemist NERC NOC PET Radiopharmaceutical Manufacturing Chemist Massachusetts General Hospital More Science jobs from Drug Discovery EVENT 2nd Annual Biomarkers in Drug Discovery & Development 09.10.13 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.